5Stoll T, Stucki G, Malik J, et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol, 1997, 24: 309-313.
6Rapp CA, Berner B, Muller GA, et al.Long-term analysis of clinical disease activity and chronic organ damage in patients with systemic lupus erythematosus. Z Rheumatol, 2002, 61: 521-531.
7Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
8Gladman DD, Urowitz MB, Kagal A, et al.Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol, 2000, 27: 377-379.
9Smolen JS. Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res, 2002, 4 Suppl 3: S25-30.
10[No authors listed]. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Arthritis Rheum, 1999, 42: 17g5-1796.
3Mohan C, Shi Y, Laman JD,et al. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol, 1995,154(3): 1470-1480.
4Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science, 1994,265(5176): 1225-1227.
5Sfikakis PP, Via CS. Expression of CD28, CTLA4, CD80, and CD86molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy. Clin Immunol Immunopathol, 1997,83(3 ): 195-198.
6Liblau R, Tisch R, Bercovici N,et al. Systemic antigen in the treatment of T- cell- mediated autoimmune diseases. Immunol Today, 1997,18 ( 12 ): 599 -604.
7Zimmerman R, Radhakrishnan J, Valeri A, et al. Advances in the treatment of lupus nephritis. Annu Rev Med,2001,52:63-78.
8Strand V, Lee M. Intravenous immunoglobulin in the treatment of autoimmune disease. In Strand V, Scott DL, Simon LS: Novel therapeutic agents for the treatment of autoimmune disease. New York: Dekker, 1997.235-256.
9Weisman MH, Bluestein HG, Bemer CM, et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol, 1997,24(2) :314-318.
2Clowse MEB. Lupus activity in pregnancy [ J]. Rheum Dis Clin North Am,2007,33(2) :237-252.
3Cortes-Hernandez J, Ordi-Ros J. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 regnancies [ J ]. Rheumatology ( Oxford ) , 2002,41 ( 6 ) :643-650.
4Smyh A, Oliveira GH. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis [ J]. Clin J Am Soc Nephrol,2010 (5) :2060- 2068.
5Gladman D, Ibanez D. Systemic lupuseiy them atosus disease activ- ity index 2000[ J1. J Rheum a to J, 2002(29) :288-291.
6Aggarwal N, Raveendran A. Pregnancy outcome in systemic lupus erythematosus: Asia' s largest single centre study [ J ]. Arch Gyne- col Obstet,2011,284(2) :281-285.
7BOWNESS P, DAVIES K A, NORSWORTHY P J, et al. Hereditary Clq deficiency and systemic lupus erythematosus [J]. QJM, 1994, 87 (8): 455-464.
8CROSS J, JAYNE D. Diagnosis and treatment of kidney disease [J]. Best Pract Res Clin Rheumatol, 2005, 19 (5) : 785 -798.
9HOCHBERG M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J]. Arthritis Rheum, 1997, 40 (9): 1725.
10GLADMAN D D, UROWITZ M B, KAGAL A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus [ J]. J Ptheumatol, 2000, 27 (2) : 377 -379.
